medical research

by Signing the McKinley-Davis-Carson-King Letter for Medical Research Given that the budget allocated to the National Institutes of Health (NIH), which funds the non-commercial, basic medical research required to develop new medical treatments and cures, is actually lower this year than it was in 2012, it has never been more important to fight for NIH funding. To help ensure that this unique federal agency receives the resources needed to support research at universities, hospitals and other research institutions across the country, Representatives Peter King (R-NY), Susan Davis (D-CA), Andre Carson (D-IN), and David McKinley (R-WV) are circulating a sign-on letter in support of critically...
Dear Research Advocate: Fostering research and innovation has long been a multi-pronged effort ’€” government, industry, academia, patients and patient organizations, foundations, and individual philanthropists ’€” all working to advance research. The current interest shown by private philanthropists in advancing science is an echo of a phenomenon witnessed a century ago ’€” and a sign of the opportunity available in some way to all of us to accelerate medical progress and maintain our nation’€™s competitive edge. As reported in a recent front page New York Times article, private donors are stepping up in a big way at a time when scientific opportunity has never been greater. But it is...
Excerpt of an article by Research!America VP of Communications Suzanne Ffolkes and Communications Specialist Anna Briseno, published in Elsevier Connect . A panel hosted by Research!America and the Pancreatic Cancer Action Network discusses challenges and opportunities for advancing cancer research Julie Fleshman’s journey to improve outcomes for pancreatic cancer patients was inspired by her father, who died four months after receiving the diagnosis. That was in 1999. Since then, she’s been advocating for research to support early diagnosis and better treatments. “That passion drives me every day ’€“ anger mixed with hope and optimism of the future,” she said. Fleshman , President and CEO...
The House and the Senate have begun deliberations on funding levels for NIH, CDC, AHRQ, NSF and FDA for FY15. Pressure to cut federal spending this midterm election year is enormous, and we need advocates to reach out to their representatives. Members in both houses of Congress are accepting input from constituents on which priorities they should fight for. Let your representatives know that combating disabling and deadly diseases is a national imperative, and funding for the agencies committed to this fight should be included on their list of appropriations priorities. Contact them TODAY and share this alert on Facebook, Twitter and with your networks. Take action!
Dear Research Advocate: The president’€™s budget for FY15 was released Tuesday. While mostly symbolic, the president’€™s funding recommendations often serve as the ’€œfirst bid’€ in the negotiations that result in agency funding levels. That is why the president’€™s proposals for the agencies that collectively drive medical progress and play such a pivotal role in the health and safety of Americans are of such concern. The president’€™s budget proposes only slight increases for NIH, FDA and NSF in FY15, and significant cuts for CDC and AHRQ. As I said in The Huffington Post and in other media, President Obama’€™s budget does not reflect the potential the U.S. has to advance scientific...
Excerpt of an op-ed by American Heart Association CEO Nancy Brown published in the Huffington Post . Every day, all across the country, the work continues in the fight against heart disease, in ways big and small. The medical community is on the front lines, of course, treating sick patients, helping others recover and — equally importantly — educating and encouraging others how to avoid the dangerous tentacles of the No. 1 killer of Americans. Researchers are hard at work seeking answers. They are conceiving and refining tests that can help with diagnosis, and the medicines and equipment that can help with treatment and prevention. Americans from other fields contribute, too, sometimes in...
Dear Research Advocate, Ironically, the government is closed down today. But that’€™s due to a major snowstorm, not because of failure to agree on increasing the debt limit! Agreeing to increase the debt limit is an encouraging sign that this Congress, weighed down as it is by ideological and political differences, and with record- low approval rankings from the public, can get its job done! Our job is to be sure research is a top priority in this election year ’€” spoken of with conviction by all candidates and by the media and others who influence them. Standing tall among Members of Congress who champion science are the Chair and Ranking Member of the House Appropriations’€™ Commerce,...
Reps. Wolf and Fattah to Receive the Edwin C. Whitehead Award for Medical Research Advocacy at Research!America’€™s Advocacy Awards Dinner on March 12 ALEXANDRIA, Va. - February 12, 2014 -Reps. Frank Wolf (R-VA) and Chaka Fattah (D-PA) will receive the Edwin C. Whitehead Award for Medical Research Advocacy for their leadership and unwavering commitment to supporting policies that promote federal and private sector medical research and innovation. Reps. Wolf and Fattah have spearheaded efforts to create a legislative and regulatory climate conducive to medical innovation. “Representatives Wolf and Fattah are exceptional champions for research,” said Research!America Chair John Edward Porter...
Excerpt of an op-ed by the Albert and Mary Lasker Foundation President Claire Pomeroy, MD, published in the Huffington Post . As an HIV physician, I began my career early in the AIDS epidemic before effective antiviral medications existed. I held my patients’ hands as they cried when receiving their diagnosis and I went to their funerals. I saw hope in their eyes when new antivirals became available. And when protease inhibitors were licensed and “triple therapy” became the norm, I could help patients plan how they would live, rather than how they would die. Scientific breakthroughs happened only because of our nation’s commitment to biomedical research, but this power of research to make...
Guest blog post by the American Chemical Society. How has the Super Bowl’€™s economy-driving market impact grown thanks to scientific research? Can a value be placed on innovation? What is the economic impact of science and technology research? What is the return on investment of research and development? These questions were addressed at the January 30, 2014, American Chemical Society Science & the Congress briefing, Measuring Economic Growth: R&D Investments , held on Capitol Hill. Moderated by the National Academies’€™ Stephen Merrill, PhD, panelist Steve Landefeld, PhD, of the Bureau of Economic Analysis spoke on how R&D numbers are now included in gross domestic product...

Pages

Sidebar Quote

The capabilities are enormous, a little bit of research can pay off quite a bit in the long run.
Paul D’ Addario, retinitis pigmentosa patient